ABSTRACT
Gestational diabetes mellitus (GDM) is associated with increased risk of pregnancy complications and adverse perinatal outcomes. GDM often reoccurs and is associated with increased risk of subsequent diagnosis of type 2 diabetes (T2D). To improve our understanding of the aetiological factors and molecular processes driving the occurrence of GDM, including the extent to which these overlap with T2D pathophysiology, the GENetics of Diabetes In Pregnancy (GenDIP) Consortium assembled genome-wide association studies (GWAS) of diverse ancestry in a total of 5,485 women with GDM and 347,856 without GDM. Through trans-ancestry meta-analysis, we identified five loci with genome-wide significant association (p<5×10−8) with GDM, mapping to/near MTNR1B (p=4.3×10−54), TCF7L2 (p=4.0×10−16), CDKAL1 (p=1.6×10−14), CDKN2A-CDKN2B (p=4.1×10−9) and HKDC1 (p=2.9×10−8). Multiple lines of evidence pointed to genetic contributions to the shared pathophysiology of GDM and T2D: (i) four of the five GDM loci (not HKDC1) have been previously reported at genome-wide significance for T2D; (ii) significant enrichment for associations with GDM at previously reported T2D loci; (iii) strong genetic correlation between GDM and T2D; and (iv) enrichment of GDM associations mapping to genomic annotations in diabetes-relevant tissues and transcription factor binding sites. Mendelian randomisation analyses demonstrated significant causal association (5% false discovery rate) of higher body mass index on increased GDM risk. Our results provide support for the hypothesis that GDM and T2D are part of the same underlying pathology but that, as exemplified by the HKDC1 locus, there are genetic determinants of GDM that are specific to glucose regulation in pregnancy.
Competing Interest Statement
D.A.L. has received support from Roche Diagnostics and Medtronic Ltd for work unrelated to that presented here. M.I.M. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. M.I.M. is now an employee of Genentech and a holder of Roche stock. G.T., V.S., and K.S. are employees of deCODE genetics/Amgen, Inc.
Funding Statement
Funding statement is included in acknowledgements
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ALSPAC: ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (approved) ANDIS-MDC (AM): Regional ethics review committee in Lund, Sweden (approved) BiB: Bradford Research Ethics Committee (approved) BOTNIA: The Ethics Committee of Helsinki and Uusimaa Hospital District, Finland (approved) deCODE: Icelandic National Bioethics Committee (approved) EGCUT: Estonian Committee on Bioethics and Human Research (approved) ERF: Medical Ethics Committee of the Erasmus University Medical Center (approved) ESTGDM: Research Ethics Committee of the University of Tartu (approved) FinnGeDi: The Ethics Committee of Northern Ostrobothnia Hospital District, Oulu, Finland (approved) Gen3G: CHUS Ethics Review Board for Studies with Humans (approved) GIFTS: UK National Research Ethics Sevice London REC (approved) GIFTS: Ethical Review Committee of the Diabeteic Asccoaition of Bangladesh (approved) GIFTS: UK National Research Ethics Sevice Committee London - Hampstead (approved) GIFTS: Norwegian Regional Committee for Medical Health Research Ethics South East (approved) HAPO: Northwestern University Institutional Review Board (approved) HONGKONG: The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee (approved) NFBC1966: Northern Ostrobothnia Hospital District Ethical Committee (approved) NFBC1986: Northern Ostrobothnia Hospital District Ethical Committee (approved) PREDO: The Ethics Committee of Helsinki and Uusimaa Hospital District, Finland (approved) SNUH: The institutional review board of the Clinical Research Institute at Seoul National University Hospital (approved) STORK: Norwegian Regional Committee for Medical Health Research Ethics South East (approved) STORK-G: Norwegian Regional Committee for Medical Health Research Ethics South East (approved) UKBB: The UK Biobank Ethics Advisory Committee (approved) VIVA: Institutional Review Board of Harvard Pilgrim Health Care (approved)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors supervised this work.
Data Availability
GWAS summary statistics will be made available once the manuscript has been accepted for publication.
